Biohaven Ltd. — Form 8-K

Biohaven Pharmaceuticals and Ono Pharmaceutical entered into a collaboration and license agreement effective October 8, 2026. Ono receives an exclusive license to develop, manufacture, and commercialize pan IgG 1/2/4 degraders (BHV-1300, BHV-1310, BHV-1320) in Japan, South Korea, Taiwan, and ASEAN countries. Ono will pay Biohaven USD $80 million upfront, USD $20 million upon receipt of stability test results and decision to continue, and tiered royalties ranging from [***]% on Net Sales during the royalty term (ending later of: regulatory exclusivity expiration, last valid patent claim expiration, or 9 years post-First Commercial Sale). Biohaven retains exclusive rights outside the Territory and maintains manufacturing responsibility with step-in rights for Ono upon supply shortfalls.